AstraZeneca shares data from HIMALAYA, MATTERHORN Phase III studies at ESMO Asia Congress 2023 Read more
Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData Read more
Polaris Group reports phase III study results of ADI-PEG 20 plus best supportive care in advanced hepatocellular carcinoma Read more